Cited by 955Parkinson's Disease Mechanisms and TreatmentsNerve injury and regenerationNuclear Receptors and Signaling

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Functional recovery in parkinsonian monkeys treated with GDNF

Gash, Don M., Zhang, Zhiming, Ovadia, Aliza, Cass, Wayne A., Yi, Ai, Simmerman, Linda, Russell, Deborah, Martin, David, Lapchak, Paul A., Collins, Frank, Hoffer, Barry J., Gerhard, Greg A.·1996·Nature

DOI 10.1038/380252a0

Open this paper in CoChat — free account

Abstract

Parkinson's disease results from the progressive degeneration of dopamine neurons that innervate the striatum. In rodents, glial-cell-line-derived neurotrophic factor (GDNF) stimulates an increase in midbrain dopamine levels, protects dopamine neurons from some neurotoxins, and maintains injured dopamine neurons. Here we extend the rodent studies to an animal closer to the human in brain organization and function, by evaluating the effects of GDNF injected intracerebrally in rhesus monkeys that have had the symptomatology and pathophysiological features of Parkinson's disease induced by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The recipients of GDNF displayed significant improvements in three of the cardinal symptoms of parkinsonism: bradykinesia, rigidity and postural instability. GDNF administered every four weeks maintained functional recovery. On the lesioned side of GDNF-treated animals, dopamine levels in the midbrain and globus pallidus were twice as high, and nigral dopamine neurons were, on average, 20% larger, with an increased fibre density. The results indicate that GDNF may be of benefit in the treatment of Parkinson's disease.

Integrity signals

Registry

Crossref · 10.1038/380252a0

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Primate models of movement disorders of basal ganglia origin
DeLong, M. R. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90110-v · Cited by 3,824
GDNF: a Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons
Lin, L.-F. H., Doherty, D. H., Lile, J. D., Bektesh, S. L., & Collins, F. (1993) · Science · doi:10.1126/science.8493557 · Cited by 3,206
Self-citation
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Self-citation
New stereological methods for counting neurons
West, M. J. (1993) · Neurobiology of Aging · doi:10.1016/0197-4580(93)90112-o · Cited by 940
Biochemical pathophysiology of Parkinson's disease.
Hornykiewicz, O., & Kish, S. J. (1987) · PubMed · Cited by 850
Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain
Beck, K. D., Valverde, J., Alexi, T., Poulsen, K., Moffat, B., Vandlen, R. A., Rosenthal, A., & Hefti, F. F. (1995) · Nature · doi:10.1038/373339a0 · Cited by 654
A consideration of neural counting methods
Coggeshall, R. E. (1992) · Trends in Neurosciences · doi:10.1016/0166-2236(92)90339-a · Cited by 540
Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo
Hoffer, B. J., Hoffman, A. F., Bowenkamp, K., Huettl, P. F., Hudson, J., Martin, D., Lin, L.-F. H., & Gerhardt, G. A. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90218-6 · Cited by 453
Self-citation
GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo
Kearns, C. M., & Gash, D. M. (1995) · Brain Research · doi:10.1016/0006-8993(94)01366-p · Cited by 379
Self-citation
Hemiparkinsonism in monkeys after unilateral internal carotid artery artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 2

Jellinger, K. Adv. Neurol. 45, 1–18 (1986).
Hornykiewicz, O. & Kish, S. J. Adv. Neurol. 45, 19–34 (1986).

Sorted by citations

Items 201–300 of 946

Acupuncture Enhances the Synaptic Dopamine Availability to Improve Motor Function in a Mouse Model of Parkinson's Disease
Kim, S., Doo, A.-R., Park, J.-Y., Bae, H., Chae, Y., Shim, I., Lee, H., Moon, W., Lee, H., & Park, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027566 · Cited by 94
GDNF signaling implemented by GM1 ganglioside; failure in Parkinson's disease and GM1-deficient murine model
Hadaczek, P., Wu, G., Sharma, N., Ciesielska, A., Bankiewicz, K. S., Davidow, A. L., Lu, Z., Forsayeth, J., & Ledeen, R. W. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.10.010 · Cited by 93
Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons
Kishima, H., Poyot, T., Bloch, J., Dauguet, J., Condé, F., Dollé, F., Hinnen, F., Pralong, W. F., Palfi, S., Déglon, N., et al. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.03.012 · Cited by 93
Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease
Murray, T. K., Messenger, M. J., Ward, M., Woodhouse, S., Osborne, D. J., Duty, S., & O’Neill, M. J. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00842-0 · Cited by 93
Recombinant Adeno-associated Viral Vector-Mediated Glial Cell Line-Derived Neurotrophic Factor Gene Transfer Protects Nigral Dopamine Neurons after Onset of Progressive Degeneration in a Rat Model of Parkinson's Disease
Mandel, R. J., Snyder, R. O., & Leff, S. E. (1999) · Experimental Neurology · doi:10.1006/exnr.1999.7203 · Cited by 93
Neuroprotective Mechanism of Glial Cell Line‐Derived Neurotrophic Factor in Mesencephalic Neurons
Sawada, H., Ibi, M., Kihara, T., Urushitani, M., Nakanishi, M., Akaike, A., & Shimohama, S. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.741175.x · Cited by 92
Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery
Lapchak, P. A., Miller, P. J., Collins, F., & Jiao, S. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)83045-x · Cited by 92
Self-citation
TGFβ induces GDNF responsiveness in neurons by recruitment of GFRα1 to the plasma membrane
Peterziel, H., Unsicker, K., & KRIEGLSTEIN, K. G. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203115 · Cited by 91
Therapeutic Potential of Neurotrophic Factors in Neurodegenerative Diseases
Levy, Y. S., Gilgun‐Sherki, Y., Melamed, E., & Offen, D. (2005) · BioDrugs · doi:10.2165/00063030-200519020-00003 · Cited by 92
Therapeutic Potential of Nerve Growth Factors in Parkinson??s Disease
Collier, T. J., & Sortwell, C. E. (1999) · Drugs & Aging · doi:10.2165/00002512-199914040-00003 · Cited by 92
Effects of GDNF on 6‐OHDA‐induced death in a dopaminergic cell line: Modulation by inhibitors of PI3 kinase and MEK
Ugarte, S. D., Lin, E., Klann, E., Zigmond, M. J., & Perez, R. G. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10632 · Cited by 89
Ret rescues mitochondrial morphology and muscle degeneration of Drosophila Pink1 mutants
Klein, P., Müller-Rischart, A. K., Motori, E., Schönbauer, C., Schnorrer, F., Winklhofer, K. F., & Klein, R. (2014) · The EMBO Journal · doi:10.1002/embj.201284290 · Cited by 90
Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model
Dowd, E., Monville, C., Torres, E. M., Wong, L., Azzouz, M., Mazarakis, N. D., & Dunnett, S. B. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04414.x · Cited by 87
New developments in understanding the etiology of Parkinson's disease and in its treatment
Lozano, A. M., Lang, A. E., Hutchison, W. D., & Dostrovsky, J. O. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80122-0 · Cited by 87
Total Synthesis of (±)‐Merrilactone A
Chen, J., Gao, P., Yu, F., Yang, Y., Zhu, S., & Zhai, H. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200378 · Cited by 87
Trophic Restoration of the Nigrostriatal Dopaminergic Pathway in Long-Term Carotid Body-Grafted Parkinsonian Rats
Toledo‐Aral, J. J., Méndez‐Ferrer, S., Pardal, R., Echevarrı́a, M., & López‐Barneo, J. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00141.2003 · Cited by 87
Glial cell line-derived neurotrophic factor: distribution and pharmacology in the rat following a bolus intraventricular injection
Lapchak, P. A., Jiao, S., Collins, F., & Miller, P. J. (1997) · Brain Research · doi:10.1016/s0006-8993(96)01265-6 · Cited by 87
Self-citation
Antiparkinsonian and Behavioral Effects of Inactivation of the Substantia Nigra Pars Reticulata in Hemiparkinsonian Primates
Wichmann, T., Kliem, M. A., & DeLong, M. R. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7572 · Cited by 87
Glial Cell Line-Derived Neurotrophic Factor Improves Survival of Dopaminergic Neurons in Transplants of Fetal Ventral Mesencephalic Tissue
Yurek, D. M. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6884 · Cited by 87
CDNF Protein Therapy in Parkinson’s Disease
Huttunen, H. J., & Saarma, M. (2019) · Cell Transplantation · doi:10.1177/0963689719840290 · Cited by 88
GDNF applied to the MPTP-lesioned nigrostriatal system requires TGF-β for its neuroprotective action
Schober, A., Peterziel, H., von Bartheld, C. S., Simon, H. H., KRIEGLSTEIN, K. G., & Unsicker, K. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.10.005 · Cited by 86
Regulation of the Development of Mesencephalic Dopaminergic Systems by the Selective Expression of Glial Cell Line-Derived Neurotrophic Factor in Their Targets
Kholodilov, N. G., Yarygina, O., Oo, T. F., Zhang, H., Sulzer, D. L., Dauer, W. T., & Burke, R. E. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.4506-03.2004 · Cited by 86
The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model
Fernández‐Suárez, D., Celorrio, M., Riezu‐Boj, J. I., Ugarte, A., Pacheco, R., González, H., Oyarzábal, J., Hillard, C. J., Franco, R., & Aymerich, M. S. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.05.021 · Cited by 85
Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson’s Disease
Garea‐Rodríguez, E., Eesmaa, A., Lindholm, P., Schlumbohm, C., König, J., Meller, B., KRIEGLSTEIN, K. G., Helms, G., Saarma, M., & Fuchs, E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149776 · Cited by 85
The Neurotoxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Induces Apoptosis in Mouse Nigrostriatal Glia
Serra, P. A., Sciola, L., Delogu, M. R., Spano, A., Monaco, G., MIELE, E., Rocchitta, G., Miele, M., Migheli, R., & Desole, M. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202099200 · Cited by 84
Neuroprotection of striatal neurons against kainate excitotoxicity by neurotrophins and GDNF family members
Gratacòs, E., Pérez‐Navarro, E., Tolosa, E. S., Arenas, E., & Alberch, J. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00538.x · Cited by 84
Experimental Models of Parkinson's Disease: From the Static to the Dynamic
Bézard, E., Imbert, C., & Gross, C. E. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.2.71 · Cited by 83
Effect of GDNF on neuroblast proliferation and photoreceptor survival: additive protection with docosahexaenoic acid.
Politi, L. E., Rotstein, N. P., & Carri, N. G. (2001) · Americanae (AECID Library) · Cited by 83
Die Parkinson-Krankheit
Berg, D., & Riederer, P. F. (2004) · Springer eBooks · doi:10.1007/978-3-642-18741-4_8 · Cited by 83
Bcl-2 and GDNF Delivered by HSV-Mediated Gene Transfer Act Additively to Protect Dopaminergic Neurons from 6-OHDA-Induced Degeneration
Natsume, A., Mata, M. M., Goss, J. R., Huang, S., Wolfe, D. P., Oligino, T., Glorioso, J. C., & Fink, D. J. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7671 · Cited by 82
Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo
Luo, F., Wang, S., Qi, L., Song, J., Lv, T., & Bai, J. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.10.017 · Cited by 81
Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction
Matarredona, E. R., Santiago, M., Venero, J. L., Cano, J., & Machado, A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00056.x · Cited by 81
Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus)
Taylor, J. R., Elsworth, J. D., Roth, R. H., Sladek, J. R., & Redmond, D. E. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00214-5 · Cited by 80
Encapsulated cell therapy for neurodegenerative diseases: From promise to product
Emerich, D. F., Orive, G., Thanos, C. G., Tornøe, J., & Wahlberg, L. U. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.008 · Cited by 79
Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats
Lü, X., & Hagg, T. (1997) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19971124)388:3 · Cited by 79
Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study
Michel, T. M., Frangou, S., Camara, S., Thiemeyer, D., Jecel, J., Tatschner, T., Zoechling, R., & Grünblatt, E. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.06.001 · Cited by 78
Gene Therapy in Parkinsonʼs Disease
Feng, L., & Maguire‐Zeiss, K. A. (2010) · CNS Drugs · doi:10.2165/11533740-000000000-00000 · Cited by 80
PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP + in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease
Visanji, N. P., Orsi, A., Johnston, T. H., Howson, P. A., Dixon, K., Callizot, N., Brotchie, J. M., & Rees, D. D. (2008) · The FASEB Journal · doi:10.1096/fj.07-095398 · Cited by 78
GDNF-Secreting Human Neural Progenitor Cells Increase Tyrosine Hydroxylase and VMAT2 Expression in MPTP-Treated Cynomolgus Monkeys
Emborg, M. E., Ebert, A. D., Moirano, J. M., Peng, S. C., Suzuki, M., Capowski, E. E., Joers, V. L., Roitberg, B. Z., Aebischer, P., & Svendsen, C. N. (2008) · Cell Transplantation · doi:10.3727/096368908784423300 · Cited by 78
Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy
Nagatsu, T. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200061 · Cited by 78
Treatment of Parkinson???s Disease
Wu, S., & Frucht, S. J. (2005) · CNS Drugs · doi:10.2165/00023210-200519090-00001 · Cited by 78
Glial cell line‐derived neurotrophic factor–secreting genetically modified human bone marrow‐derived mesenchymal stem cells promote recovery in a rat model of Parkinson's disease
Glavaski‐Joksimovic, A., Virág, T., Mangatu, T. A., McGrogan, M. P., Wang, X. S., & Bohn, M. C. (2010) · Journal of Neuroscience Research · doi:10.1002/jnr.22435 · Cited by 77
GDNF delivery for Parkinson’s disease
Patel, N. K., & Gill, S. S. (2007) · Springer eBooks · doi:10.1007/978-3-211-33081-4_16 · Cited by 77
Neurotrophin Signaling and Stem Cells—Implications for Neurodegenerative Diseases and Stem Cell Therapy
Pramanik, S., Sulistio, Y. A., & Heese, K. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0214-7 · Cited by 77
Reactive Astrocytes of the Quinolinic Acid-Lesioned Rat Striatum Express GFRα1 as Well as GDNF in Vivo
Bresjanac, M., & Antauer, G. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7416 · Cited by 77
Application of a blood–brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease
Dietz, G. P. H., Valbuena, P., Dietz, B., Meuer, K., Müller, P., Weishaupt, J. H., & Bähr, M. (2006) · Brain Research · doi:10.1016/j.brainres.2006.01.083 · Cited by 76
EXPRESSION, BIOACTIVITY, AND SAFETY 1 YEAR AFTER ADENO-ASSOCIATED VIRAL VECTOR TYPE 2–MEDIATED DELIVERY OF NEURTURIN TO THE MONKEY NIGROSTRIATAL SYSTEM SUPPORT CERE-120 FOR PARKINSON'S DISEASE
Herzog, C. D., Brown, L., Gammon, D., Kruegel, B. R., Lin, R., Wilson, A., Bolton, A., Printz, M. A., Gasmi, M., Bishop, K. M., et al. (2009) · Neurosurgery · doi:10.1227/01.neu.0000340682.06068.01 · Cited by 75
Granulocyte macrophage-colony stimulating factor protects against substantia nigra dopaminergic cell loss in an environmental toxin model of Parkinson's disease
Mangano, E. N., Peters, S., Litteljohn, D., So, R., Bethune, C., Bobyn, J., Clarke, M., & Hayley, S. P. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.02.011 · Cited by 75
Constitutive Ret Activity in Knock-In Multiple Endocrine Neoplasia Type B Mice Induces Profound Elevation of Brain Dopamine Concentration via Enhanced Synthesis and Increases the Number of TH-Positive Cells in the Substantia Nigra
Mijatovic, J., Airavaara, M., Planken, A., Auvinen, P., Raasmaja, A., Piepponen, P. T., Costantini, F. D., Ahtee, L., & Saarma, M. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5647-06.2007 · Cited by 75
Activation of Nigral and Pallidal Dopamine D1-Like Receptors Modulates Basal Ganglia Outflow in Monkeys
Kliem, M. A., Maidment, N. T., Ackerson, L. C., Chen, S., Smith, Y., & Wichmann, T. (2007) · Journal of Neurophysiology · doi:10.1152/jn.00171.2007 · Cited by 75
Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine and astrocytic modulation
Fan, Y., Kong, H., Shi, X., Sun, X., Ding, J., Wu, J., & Hu, G. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.015 · Cited by 75
Analysis of the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3'-UTR and alternative splice products
Grimm, L. L., Holinski‐Feder, E., Teodoridis, J. M., Scheffer, B., Schindelhauer, D., Meitinger, T., & Ueffing, M. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.12.1873 · Cited by 75
Chronic, intermittent convection-enhanced delivery devices
Lewis, O. T., Woolley, M., Johnson, D., Rosser, A., Barua, N. U., Bienemann, A. S., Gill, S. S., & Evans, S. L. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.11.008 · Cited by 75
Persephin-Overexpressing Neural Stem Cells Regulate the Function of Nigral Dopaminergic Neurons and Prevent Their Degeneration in a Model of Parkinson's Disease
PKERUD, P., Holm, P. C., Castelo‐Branco, G., Sousa, K. M., Rodríguez, F. J., & Arenas, E. (2002) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2002.1171 · Cited by 75
RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
Mahato, A. K., & Sidorova, Y. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197108 · Cited by 75
A Monoclonal Antibody-GDNF Fusion Protein Is Not Neuroprotective and Is Associated with Proliferative Pancreatic Lesions in Parkinsonian Monkeys
Ohshima-Hosoyama, S., Simmons, H. A., Goecks, N. C., Joers, V. L., Swanson, C. R., Bondarenko, V., Velotta, R., Brunner, K. G., Wood, L. D., Hruban, R. H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039036 · Cited by 74
Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease
Beckstrøm, H., Julsrud, L., Haugeto, Ø., Dewar, D., Graham, D. I., Lehre, K. P., Storm‐Mathisen, J., & Danbolt, N. C. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19990115)55:2 · Cited by 96
Neuroprotective and neurodegenerative effects of the chronic expression of tumor necrosis factor α in the nigrostriatal dopaminergic circuit of adult mice
Chertoff, M., Paolo, N. D., Schöneberg, A., Depino, A. M., Ferrari, C. C., Wurst, W., Pfizenmaier, K., Eisel, U. L. M., & Pitossi, F. J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.11.010 · Cited by 73
The role of transcription factor Pitx3 in dopamine neuron development and Parkinson's disease.
Li, J., Dani, J. A., & Le, W. (2009) · PubMed · Cited by 73
Transgene Expression, Bioactivity, and Safety of CERE-120 (AAV2-Neurturin) Following Delivery to the Monkey Striatum
Herzog, C. D., Dass, B., Gasmi, M., Bakay, R., Stansell, J. E., Tuszynski, M., Bankiewicz, K., Chen, E.-Y., Chu, Y., Bishop, K., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.170 · Cited by 72
Neurotrophic factors for the treatment of Parkinson's disease
Sullivan, A. M., & Toulouse, A. (2011) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2011.05.001 · Cited by 72
Multifunctional tellurium molecule protects and restores dopaminergic neurons in Parkinson's disease models
Sredni, B., Geffen, R., Duan, W., Albeck, M., Shalit, F., Lander, H. M., Kinor, N., Sagi, O., Albeck, A., Yosef, S., et al. (2007) · The FASEB Journal · doi:10.1096/fj.06-7500com · Cited by 72
Differences in Pharmacological Properties of Dopamine Release Between the Substantia Nigra and Striatum: An In Vivo Electrochemical Study
Hoffman, A. F., & Gerhardt, G. A. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38157-1 · Cited by 72
Protection of nigral neurons by GDNF-engineered marrow cell transplantation
Park, K. W., Eglitis, M. A., & Mouradian, M. M. (2001) · Neuroscience Research · doi:10.1016/s0168-0102(01)00242-5 · Cited by 71
GDNF and protection of adult central catecholaminergic neurons
Pascual, A., Hidalgo‐Figueroa, M., Gómez-Díaz, R., & López‐Barneo, J. (2011) · Journal of Molecular Endocrinology · doi:10.1530/jme-10-0125 · Cited by 72
The impact of metabotropic glutamate receptors into active neurodegenerative processes: A “dark side” in the development of new symptomatic treatments for neurologic and psychiatric disorders
Bruno, V., Caraci, F., Copani, A., Matrisciano, F., Nicoletti, F., & Battaglia, G. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.044 · Cited by 73
Apoptosis in neurodegenerative disorders
Mochizuki, H., Mori, H., & Mizuno, Y. (1997) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6842-4_13 · Cited by 71
Advancing neurotrophic factors as treatments for age-related neurodegenerative diseases: developing and demonstrating “clinical proof-of-concept” for AAV-neurturin (CERE-120) in Parkinson's disease
Bartus, R. T., Baumann, T. L., Brown, L., Kruegel, B. R., Ostrove, J. M., & Herzog, C. D. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.07.018 · Cited by 70
Effects of chronic intraputamenal infusion of glial cell line-derived neurotrophic factor (GDNF) in aged Rhesus monkeys
Maswood, N., Grondin, R., Zhang, Z., Stanford, J. A., Surgener, S. P., Gash, D. M., & Gerhardt, G. A. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00022-2 · Cited by 70
Self-citation
Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease
Walker, D. G., Beach, T. G., Xu, R., Lile, J. D., Beck, K. D., McGeer, E. G., & McGeer, P. L. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00131-0 · Cited by 70
Clinical neuroprotection in Parkinson's disease — Still waiting for the breakthrough
Löhle, M., & Reichmann, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.08.025 · Cited by 70
Factors promoting survival of mesencephalic dopaminergic neurons
KRIEGLSTEIN, K. G. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0920-8 · Cited by 70
Development of a Maturing T-Cell-Mediated Immune Response in Patients with Idiopathic Parkinson’s Disease Receiving r-metHuGDNF Via Continuous Intraputaminal Infusion
Tatarewicz, S. M., Wei, X. L., Gupta, S., Masterman, D. M., Swanson, S. J., & Moxness, M. S. (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9117-8 · Cited by 68
GDNF reduces oxidative stress in a 6-hydroxydopamine model of Parkinson's disease
Smith, M. P., & Cass, W. A. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.017 · Cited by 68
Self-citation
Recombinant Adeno-Associated Virus Vector Expressing Glial Cell Line-Derived Neurotrophic Factor Reduces Ischemia-Induced Damage
Tsai, T.-H., Chen, S.-L., Chiang, Y.-H., Lin, S.-Z., Ma, H.-I., Kuo, S.-W., & Tsao, Y.-P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7505 · Cited by 67
Bone-marrow-derived cell differentiation into microglia: A study in a progressive mouse model of Parkinson's disease
Rodrı́guez, M., Alvarez‐Erviti, L., Blesa, F. J., Rodríguez‐Oroz, M., Arina, A., Melero, I., Ramos, L. I., & Obeso, J. A. (2007) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.07.024 · Cited by 67
A Non-invasive System for Delivering Neural Growth Factors across the Blood-Brain Barrier: A Review
Granholm, A., Albeck, D. S., Bäckman, C. M., Curtis, M., Ebendal, T., Friden, P. M., Henry, M. A., Hoffer, B. J., Kordower, J. H., Rose, G. M., et al. (1998) · Reviews in the Neurosciences · doi:10.1515/revneuro.1998.9.1.31 · Cited by 67
Self-citation
Trophic factors for Parkinson's disease: To live or let die
Olanow, C. W., Bartus, R. T., Volpicelli‐Daley, L. A., & Kordower, J. H. (2015) · Movement Disorders · doi:10.1002/mds.26426 · Cited by 66
SINEUP Non-coding RNA Targeting GDNF Rescues Motor Deficits and Neurodegeneration in a Mouse Model of Parkinson’s Disease
Espinoza, S., Scarpato, M., Damiani, D., Managò, F., Mereu, M., Contestabile, A., Peruzzo, O., Carninci, P., Santoro, C., Papaleo, F., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.08.005 · Cited by 67
Insights into lncRNAs in Alzheimer’s disease mechanisms
Li, D., Zhang, J., Li, X., Chen, Y., Feng, Y., & Liu, Q. (2020) · RNA Biology · doi:10.1080/15476286.2020.1788848 · Cited by 68
Neurotrophic factors for disease-modifying treatments of Parkinson's disease: gaps between basic science and clinical studies
Chmielarz, P., & Saarma, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00120-3 · Cited by 69
Selective Glial Cell Line-Derived Neurotrophic Factor Production in Adult Dopaminergic Carotid Body CellsIn Situand after Intrastriatal Transplantation
Villadiego, J., Méndez‐Ferrer, S., Valdés‐Sánchez, T., Silos‐Santiago, I., Fariñas, I., López‐Barneo, J., & Toledo‐Aral, J. J. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.4312-04.2005 · Cited by 66
1,25-Dihydroxyvitamin D3 increases striatal GDNF mRNA and protein expression in adult rats
Sánchez, B., López-Martín, M. E., Segura, C., Labandeira-García, J. L., & Pérez-Fernández, R. (2002) · Molecular Brain Research · doi:10.1016/s0169-328x(02)00545-4 · Cited by 66
Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats
Fujikawa, T., Miguchi, S., Kanada, N., Nakai, N., Ogata, M., Suzuki, I., & Nakashima, K. (2005) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.11.031 · Cited by 66
Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons
Feng, L., Wang, C.-Y., Jiang, H., Oho, C., Mizuno, K., Dugich‐Djordjevic, M. M., & Lu, B. (1999) · Molecular Brain Research · doi:10.1016/s0169-328x(99)00015-7 · Cited by 66
Morphological Alterations in the Peripheral and Central Nervous Systems of Mice Lacking Glial Cell Line-Derived Neurotrophic Factor (GDNF): Immunohistochemical Studies
Granholm, A., Srivastava, N., Mott, J. L., Henry, S., Henry, M. A., Westphal, H., Pichel, J. G., Shen, L., & Hoffer, B. J. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-03-01168.1997 · Cited by 66
Self-citation
Brain delivery of microencapsulated GDNF induces functional and structural recovery in parkinsonian monkeys
Garbayo, E., Ansorena, E., Lana, H., Carmona‐Abellán, M., Marcilla, I., Lanciego, J. L., Luquín, M. R., & Blanco‐Prieto, M. J. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.09.015 · Cited by 65
Sustained delivery of GDNF: towards a treatment for Parkinson’s disease
Zurn, A. D., Widmer, H. R., & Aebischer, P. (2001) · Brain Research Reviews · doi:10.1016/s0165-0173(01)00098-4 · Cited by 65
Current Status and Challenges Associated with CNS-Targeted Gene Delivery across the BBB
Kimura, S., & Harashima, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12121216 · Cited by 65
Glial Cell Line-Derived Neurotrophic Factor (GDNF) Gene Delivery Protects Dopaminergic Terminals from Degeneration
Connor, B. J., Kozlowski, D. A., Unnerstall, J. R., Elsworth, J. D., Tillerson, J. L., Schallert, T. J., & Bohn, M. C. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7638 · Cited by 64
GDNF therapy for Parkinson’s disease
Hong, M. G. L., Mukhida, K., & Mendez, I. M. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.7.1125 · Cited by 64
Glial cell line-derived neurotrophic factor-conjugated nanoparticles suppress acquisition of cocaine self-administration in rats
Green-Sadan, T., Kuttner, Y., Lublin‐Tennenbaum, T., Kinor, N., Boguslavsky, Y., Margel, S., & Yadid, G. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.01.020 · Cited by 64
Cloning and Characterization of Murine Glial Cell-Derived Neurotrophic Factor Inducible Transcription Factor (MGIF)
Yajima, S., Lammers, C., Lee, S.-H., Hara, Y., Mizuno, K., & Mouradian, M. M. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-22-08657.1997 · Cited by 64
Motoneurons crave glial cell line-derived neurotrophic factor
Bohn, M. C. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.012 · Cited by 63
Glial cell line-derived neurotrophic factor protects against ischemia/hypoxia-induced brain injury in neonatal rat
Ikeda, T., Xia, X., Xia, Y., Ikenoue, T., Han, B., & Choi, B. H. (2000) · Acta Neuropathologica · doi:10.1007/s004019900162 · Cited by 63
Adenovirus-Mediated Transduction with Human Glial Cell Line-Derived Neurotrophic Factor Gene Prevents 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Induced Dopamine Depletion in Striatum of Mouse Brain
Kojima, H., Abiru, Y., Sakajiri, K., Watabe, K., Ohishi, N., Takamori, M., Hatanaka, H., & Yagi, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7183 · Cited by 63
The messenger RNAs for both glial cell line-derived neurotrophic factor receptors, c- ret and GDNFRα, are induced in the rat brain in response to kainate-induced excitation
Reeben, M., Laurikainen, A., Hiltunen, J. O., Ċastrén, E., & Saarma, M. (1998) · Neuroscience · doi:10.1016/s0306-4522(97)00361-8 · Cited by 63
Phospholipase Cγ in Distinct Regions of the Ventral Tegmental Area Differentially Modulates Mood-Related Behaviors
Bolaños, C. A., Perrotti, L. I., Edwards, S., Eisch, A. J., Barrot, M., Olson, V. G., Russell, D. S., Neve, R. L., & Nestler, E. J. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-20-07569.2003 · Cited by 62
Self-citation
Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease
O’Neill, M. J., Murray, T. K., Whalley, K., Ward, M., Hicks, C. A., Woodhouse, S., Osborne, D. J., & Skolnick, P. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.023 · Cited by 62
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson’s disease
Dass, B., Olanow, C. W., & Kordower, J. H. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s89 · Cited by 62

Authors: Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., Hoffer, B. J., & Gerhard, G. A.
Affiliations: University of Kentucky (US)
ORCID: Gash, Don M.
Zhang, Zhiming
Cass, Wayne A.
Lapchak, Paul A.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 1996-03
Volume: 380
Issue: 6571
Pages: 252-255
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/380252a0
OpenAlex: W1971258758
Cited by: 955
References: 22
Citations by year: 2026: 2 · 2025: 12 · 2024: 10 · 2023: 9 · 2022: 20 · 2021: 16 · 2020: 23 · 2019: 18 · 2018: 20 · 2017: 13 · 2016: 21 · 2015: 27 · 2014: 24 · 2013: 30 · 2012: 27
FWCI: 51.18
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: Parkinson's disease, glial cell line-derived neurotrophic factor, MPTP-induced parkinsonism, rhesus monkeys, dopaminergic neurons, midbrain dopamine, globus pallidus, nigral neurons, bradykinesia, rigidity, postural instability, functional recovery, neuroprotection, neurotrophic therapy
MeSH terms: Animals, Dopamine, Female, Humans, Macaca mulatta, Mesencephalon, Nerve Growth Factors, Nerve Tissue Proteins, Neurons, Parkinson Disease, Recombinant Proteins, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Glial Cell Line-Derived Neurotrophic Factor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Functional recovery in parkinsonian monkeys treated with GDNF

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks